Wealth Enhancement Advisory Services LLC Invests $301,000 in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Wealth Enhancement Advisory Services LLC bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,564 shares of the company's stock, valued at approximately $301,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares in the last quarter. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $61,000. KLP Kapitalforvaltning AS bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $158,000. Bellevue Group AG bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $160,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Kiniksa Pharmaceuticals International by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after acquiring an additional 4,575 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 12,336 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $30.39, for a total transaction of $374,891.04. Following the completion of the sale, the director owned 12,546 shares of the company's stock, valued at approximately $381,272.94. This trade represents a 49.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ross Moat sold 27,594 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the sale, the insider directly owned 9,415 shares of the company's stock, valued at $273,223.30. This represents a 74.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 440,863 shares of company stock valued at $12,101,029 in the last ninety days. Insiders own 53.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on KNSA shares. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Wedbush reissued an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Sunday, July 6th. Finally, Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $39.33.

Kiniksa Pharmaceuticals International Trading Down 3.0%

Shares of KNSA traded down $0.86 on Friday, reaching $28.09. 355,269 shares of the company's stock traded hands, compared to its average volume of 555,944. The stock has a market cap of $2.05 billion, a PE ratio of -112.36 and a beta of 0.05. The stock's 50 day simple moving average is $27.72 and its two-hundred day simple moving average is $23.17. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. Kiniksa Pharmaceuticals International's revenue was up 72.5% on a year-over-year basis. During the same period last year, the business posted ($0.25) earnings per share. Analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.